Dr. Nikkia Diaz, M.D. Internal Medicine - Infectious Disease Medicare: Medicare Enrolled Practice Location: 46 Albion St, Bridgeport, CT 06605 Phone: 203-330-6000 |
Kerry Elizabeth Wilson, M.D. Internal Medicine - Infectious Disease Medicare: Medicare Enrolled Practice Location: 510 Clinton Ave, Bridgeport, CT 06605 Phone: 203-330-6000 |
Grace P Kim, MD Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4699 Main St Ste 201, Bridgeport, CT 06606 Phone: 203-659-1599 Fax: 203-382-0189 |
News Archive
Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.
The Los Angeles Times: "When Senate Democratic leaders agreed this week to remove a public insurance plan from their massive healthcare bill, they did more than quash a liberal dream of expanding the government safety net. They effectively pinned their hopes of guaranteeing coverage to all Americans on a far more conventional prescription: government regulation.
Over the last few years, researchers have used a type of brain scanning, known as functional magnetic resonance imaging fMRI, to help them map changes in blood flow in the brain and to correlate this with thoughts and behavior. A new way to analyze fMRI data, which could improve is reported in the International Journal of Computational Biology and Drug Design.
The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by the Cancer Genome Atlas (TCGA) Research Network. The researchers of this study also found that response to aggressive chemotherapy and radiation differed by subtype.
› Verified 6 days ago